Clinical Trial Goal
To find out if loncastuximab tesirine is safe and works well to treat B-cell lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years or older
- Have B-cell lymphoma that has relapsed or is refractory. Some examples include:
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Mantle cell lymphoma (MCL)
- Neoplastic post-transplant lymphoproliferative disorder
- Non-Hodgkin lymphoma (NHL)
- Have not been treated with loncastuximab tesirine
- Do not have graft versus host disease (GVHD)
- Do not have lymphoma in your brain or spinal cord
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Loncastuximab tesirine is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Loncastuximab tesirine – Given as an intravenous (IV) infusions 1 time
You may continue treatment for about 4 months. You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved loncastuximab tesirine.
Locations
Fred Hutch/University of Washington Cancer ConsortiumRECRUITING
Seattle, Washington
Stephen D. Smith, 206-606-6546, ssmith50@fredhutch.org
Sponsors
lead: University of Washington
